Microbubble

Phase 3Small molecule

NNaviFUS Corporation

Microbubble is one of 57 small molecule programs targeting Glioblastoma Multiforme. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glioblastoma MultiformeActive, not recruiting

Glioblastoma MultiformePhase 3

Active, not recruiting

Competition

Competitive Landscape

292 competitors in Glioblastoma Multiforme

#DrugCompanyPhaseTrials

Bicnu

MMelissa K Accordino

Phase 3

10 2

Aralen

Sanofi

Phase 3

1 3

Arava

Sanofi

Phase 3

1 4

Ceenu

AAzurity Pharmaceuticals

Phase 3

6 5

Yervoy

Opdivo

Veliparib

2 8

Enzastaurin

Eli Lilly

Phase 3

1 9

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Thalomid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Recruiting

Glioblastoma Multiforme

NCT06496971

Clinical

Trials by Indication[1]

Glioblastoma Multiforme1 trial

A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

Recruiting·NNaviFUS Corporation·Phase 3·NCT06496971·32 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Microbubble. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Microbubble compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Microbubble. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NaviFUS Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNaviFUS Corporation

Microbubble

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Glioblastoma Multiforme1 trial

References

Drug Info

Quick Facts

Related News